211 related articles for article (PubMed ID: 8779116)
1. [The efficacy of the Umex treatment of parkinsonism patients in the initial stage of the disease].
Fedorova NV; Glozman ZhM; Saltykova NM
Ter Arkh; 1995; 67(10):75-7. PubMed ID: 8779116
[TBL] [Abstract][Full Text] [Related]
2. [Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients].
Stoliarova LG; Kadykov AS; Shvedkov VV; Shakhparonova NV
Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(12):11-3. PubMed ID: 3149842
[TBL] [Abstract][Full Text] [Related]
3. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
[TBL] [Abstract][Full Text] [Related]
4. [Use of iumeks in the combined therapy of parkinsonism patients ].
Man'kovskiĭ NB; Karaban' IN; Mialovitskaia EA
Vrach Delo; 1987 Aug; (8):100-2. PubMed ID: 3120415
[No Abstract] [Full Text] [Related]
5. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
6. Selegiline slows the progression of the symptoms of Parkinson disease.
Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
[TBL] [Abstract][Full Text] [Related]
7. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
8. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
[TBL] [Abstract][Full Text] [Related]
9. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
10. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.
Waters CH; Sethi KD; Hauser RA; Molho E; Bertoni JM;
Mov Disord; 2004 Apr; 19(4):426-32. PubMed ID: 15077240
[TBL] [Abstract][Full Text] [Related]
11. [Effects of sleep deprivation in patients with parkinsonism].
Levin IaI
Sov Med; 1991; (11):9-11. PubMed ID: 1767333
[TBL] [Abstract][Full Text] [Related]
12. [Present-day treatment of parkinsonism in the aged].
Siegfried J
Schweiz Rundsch Med Prax; 1973 Oct; 62(40):1202-3. PubMed ID: 4754539
[No Abstract] [Full Text] [Related]
13. [Experience using veroshpiron in the combined therapy of parkinsonism].
Vartanian KZ; Karimova MKh
Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(12):14-8. PubMed ID: 3245369
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
[TBL] [Abstract][Full Text] [Related]
16. Clinical effects of L-threo-3,4-dihydroxyphenylserine in cases of parkinsonism and pure akinesia.
Narabayashi H; Kondo T; Yokochi F; Nagatsu T
Adv Neurol; 1987; 45():593-602. PubMed ID: 3103397
[No Abstract] [Full Text] [Related]
17. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
Buchwald B; Angersbach D; Jost WH
Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
[TBL] [Abstract][Full Text] [Related]
18. Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials.
Gunzler SA; Pavel M; Koudelka C; Carlson NE; Nutt JG
Clin Neuropharmacol; 2009; 32(2):97-102. PubMed ID: 18978495
[TBL] [Abstract][Full Text] [Related]
19. The influence of a previous thalamotomy on the L-dopa effects on mono-manual dexterity in parkinsonism.
Knutsson E; Mårtensson A; Meyerson BA; Risberg AM
Scand J Rehabil Med; 1973; 5(3):130-3. PubMed ID: 4754551
[No Abstract] [Full Text] [Related]
20. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
